| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11642317 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US11596599 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
Eysuvis is owned by Alcon Labs Inc.
Eysuvis contains Loteprednol Etabonate.
Eysuvis has a total of 2 drug patents out of which 0 drug patents have expired.
Eysuvis was authorised for market use on 26 October, 2020.
Eysuvis is available in suspension/drops;ophthalmic dosage forms.
Eysuvis can be used as a method for treating dry eye in a patient.
The generics of Eysuvis are possible to be released after 03 May, 2033.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product (NP) | Oct 26, 2023 |
Drugs and Companies using LOTEPREDNOL ETABONATE ingredient
Market Authorisation Date: 26 October, 2020
Treatment: A method for treating dry eye in a patient
Dosage: SUSPENSION/DROPS;OPHTHALMIC
EYSUVIS family patents
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11219596 | KALA PHARMS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US10857096 | KALA PHARMS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US10945948 | KALA PHARMS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US10940108 | KALA PHARMS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US9532955 | KALA PHARMS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US9737491 | KALA PHARMS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US9056057 | KALA PHARMS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US9827191 | KALA PHARMS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US10058511 | KALA PHARMS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US10993908 | KALA PHARMS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US10688045 | KALA PHARMS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US9393213 | KALA PHARMS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US10646436 | KALA PHARMS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
Eysuvis is owned by Kala Pharms Inc.
Eysuvis contains Loteprednol Etabonate.
Eysuvis has a total of 13 drug patents out of which 0 drug patents have expired.
Eysuvis was authorised for market use on 26 October, 2020.
Eysuvis is available in suspension/drops;ophthalmic dosage forms.
Eysuvis can be used as a method for treating dry eye in a patient, administration to the eye of a patient for treatment of dry eye condition, a method for delivering a composition to a mucus membrane, a method for delivering a pharmaceutical agent across a mucosal barrier.
The generics of Eysuvis are possible to be released after 03 May, 2033.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product (NP) | Oct 26, 2023 |
Drugs and Companies using LOTEPREDNOL ETABONATE ingredient
Market Authorisation Date: 26 October, 2020
Treatment: A method for treating dry eye in a patient; A method for delivering a composition to a mucus membrane; A method for delivering a pharmaceutical agent across a mucosal barrier; Administration to the ey...
Dosage: SUSPENSION/DROPS;OPHTHALMIC
EYSUVIS family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic